Intellectual Property India Publishes Patent Application for 'Anti-Her3 Antibody-Drug Conjugate Composition And Pharmaceutical Use Thereof' Filed by Suzhou Suncadia Biopharmaceuticals Co. Ltd.; Shanghai Hengrui Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Pharmaceuticals Co. Ltd.

MUMBAI, India, June 27 -- Intellectual Property India has published a patent application (202527053055 A) filed by Suzhou Suncadia Biopharmaceuticals Co. Ltd.; Shanghai Hengrui Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Pharmaceuticals Co. Ltd., Jiangsu, China, on May 31, for 'anti-her3 antibody-drug conjugate composition and pharmaceutical use thereof.'

Inventor(s) include Yang, Xiqin; Ge, Lingxiao; Yang, Zhen; and Wang, Hongwei.

The application for the patent was published on June 27, under issue no. 26/2025.

According to the abstract released by the Intellectual Property India: "The present invention relates to an anti-HER3 antibody-drug conjugate composition and pharmaceutical use thereof. Specifically, the composition of the present invention comprises an anti-HER3 antibody-drug conjugate and a buffering agent."

The patent application was internationally filed on Nov. 28, 2023, under International application No.PCT/CN2023/134686.

Disclaimer: Curated by HT Syndication.